62 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 Jun 24
Entry into a Material Definitive Agreement
5:26pm
, but for other infectious diseases that present significant endemic and pandemic threats.”
Vaxart was the first U.S. company to complete a Phase 2 clinical
8-K
EX-99.1
p51e2800vw9w i41
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
8-K
EX-99.1
pnu5kil9xfy7rriz
8 Nov 22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4:10pm
8-K
EX-99.1
nczl0d4k99rm252d
28 Jun 22
Other Events
5:09pm
8-K
EX-10.1
q53y5425zz g367djnd
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.2
3jvh8odj5uxulaavk
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm